A 48-year-old man with bipolar disorder has been on lithium carbonate 1200 mg daily for 5 years. He attends the psychiatry clinic for routine follow-up. Serum lithium level is 1.0 mEq/L (therapeutic range 0.6–1.2 mEq/L). On questioning, he reports persistent polyuria (3–4 liters/day), polydipsia, and mild tremor. Serum creatinine is 1.3 mg/dL (baseline 0.9 mg/dL 2 years ago), eGFR 52 mL/min/1.73m², serum sodium 138 mEq/L, serum calcium 10.2 mg/dL (normal 8.5–10.2), serum TSH 4.8 mIU/L (normal 600 mOsm/kg after water restriction). What is the most likely chronic adverse effect of lithium, and what is the next step in management?

Question

A 48-year-old man with bipolar disorder has been on lithium carbonate 1200 mg daily for 5 years. He attends the psychiatry clinic for routine follow-up. Serum lithium level is 1.0 mEq/L (therapeutic range 0.6–1.2 mEq/L). On questioning, he reports persistent polyuria (3–4 liters/day), polydipsia, and mild tremor. Serum creatinine is 1.3 mg/dL (baseline 0.9 mg/dL 2 years ago), eGFR 52 mL/min/1.73m², serum sodium 138 mEq/L, serum calcium 10.2 mg/dL (normal 8.5–10.2), serum TSH 4.8 mIU/L (normal <4.0). Urine osmolality is 180 mOsm/kg (normal >600 mOsm/kg after water restriction). What is the most likely chronic adverse effect of lithium, and what is the next step in management?

Accepted Answer

C. Lithium-induced nephrogenic diabetes insipidus; switch to an alternative mood stabilizer such as valproate. ## Chronic Lithium Toxicity: Nephrogenic Diabetes Insipidus

### Clinical Presentation of Chronic Lithium Effects

This patient exhibits a constellation of findings consistent with **lithium-induced nephrogenic diabetes insipidus (NDI)**:

| Finding | Significance |
|---------|-------------|
| **Polyuria (3–4 L/day) + polydipsia** | Classic NDI presentation; inability to concentrate urine |
| **Low urine osmolality (180 mOsm/kg)** | Diagnostic: inability to concentrate urine despite water restriction |
| **Elevated serum creatinine** | Progressive renal dysfunction (0.9 → 1.3 mg/dL over 2 years) |
| **Reduced eGFR (52 mL/min/1.73m²)** | Stage 3a chronic kidney disease; lithium-induced |
| **Mild tremor** | Early sign of chronic lithium accumulation |
| **Serum lithium 1.0 mEq/L** | Within therapeutic range, but chronic exposure causes irreversible renal damage |

### Mechanism of Lithium-Induced Nephrogenic Diabetes Insipidus

```mermaid
flowchart TD
  A[Lithium enters collecting duct cells]:::action --> B[Inhibits adenylyl cyclase]:::action
  B --> C[Reduces cAMP production]:::action
  C --> D[Impairs aquaporin-2 channel insertion]:::action
  D --> E[Collecting duct becomes unresponsive to ADH]:::outcome
  E --> F[Inability to concentrate urine]:::outcome
  F --> G[Polyuria + polydipsia]:::outcome
  G --> H[Chronic dehydration → renal hypoperfusion]:::action
  H --> I[Progressive interstitial fibrosis & CKD]:::urgent
```

**Key Point:**
Lithium-induced NDI is **dose-dependent and potentially irreversible**. Chronic exposure (even at therapeutic levels) causes structural damage to the collecting duct and interstitial fibrosis. The longer the duration of lithium therapy, the greater the risk.

**High-Yield:**
- **Incidence:** 20–40% of patients on chronic lithium develop polyuria; 10–20% develop overt NDI
- **Onset:** Can occur within months but typically after years of therapy
- **Reversibility:** Partial reversal may occur if lithium is stopped early; late-stage fibrosis is irreversible
- **Diagnostic test:** Water restriction test → urine osmolality remains <300 mOsm/kg (true NDI, not psychogenic polydipsia)

### Management Strategy

**Step 1: Confirm the diagnosis**
- Water restriction test (already done; urine osmolality 180 mOsm/kg confirms NDI)
- Assess renal function trend (creatinine rising over 2 years)

**Step 2: Risk-benefit reassessment**
- If lithium is essential for mood stability and no safer alternative exists → continue with close monitoring
- If alternative mood stabilizers are available and effective → **switch to valproate, lamotrigine, or atypical antipsychotics**

**Step 3: If continuing lithium**
- Reduce to lowest effective dose
- Monitor serum lithium, creatinine, and eGFR every 6 months
- Counsel patient on adequate hydration
- Consider amiloride (potassium-sparing diuretic) if NDI is severe and lithium cannot be stopped

**Clinical Pearl:**
Amiloride blocks lithium entry into collecting duct cells (via ENaC channels) and can partially reverse lithium-induced NDI. Dose: 5–10 mg daily. Monitor potassium and renal function.

### Why This Is the Correct Answer

**Mnemonic: LITHIUM CHRONIC TOXICITY = LEND**
- **L**ithium-induced
- **E**ndocrine (hypothyroidism, hyperparathyroidism)
- **N**ephrogenic diabetes insipidus
- **D**iabetes insipidus, renal dysfunction

The clinical triad of polyuria, low urine osmolality despite water restriction, and progressive renal dysfunction is pathognomonic for lithium-induced NDI.

[cite:Kaplan & Sadock's Synopsis of Psychiatry 12e, Ch. 31; Harrison's Principles of Internal Medicine 21e, Ch. 468]

Answer

A. Acute kidney injury from dehydration; increase fluid intake and monitor renal function

Answer

B. Primary hypothyroidism; add levothyroxine and continue lithium at current dose

Answer

D. Lithium-induced hypercalcemia with secondary hyperparathyroidism; reduce lithium dose and check parathyroid hormone

Explanation

Practice similar questions